An overview on synthetic and biological activities of cannabidiol (CBD) and its derivatives.

[1]  Jirong Luo,et al.  Enantioselective Total Synthesis of Cannabinoids via a Tandem Conjugate Addition/Enolate Alkylation Annulation with Ambiphilic Organoboronates. , 2023, Organic letters.

[2]  J. Muscat,et al.  Inhibition of Nicotine Metabolism by Cannabidiol (CBD) and 7-Hydroxycannabidiol (7-OH-CBD) , 2023, Chemical research in toxicology.

[3]  Qi Wu,et al.  8,9-Dihydrocannabidiol, an Alternative of Cannabidiol, Its Preparation, Antibacterial and Antioxidant Ability , 2023, Molecules.

[4]  P. Trivedi,et al.  Selective CB2 Receptor Agonist, HU-308, Reduces Systemic Inflammation in Endotoxin Model of Pneumonia-Induced Acute Lung Injury , 2022, International journal of molecular sciences.

[5]  C. Bladen,et al.  The anticonvulsant phytocannabinoids CBGVA and CBDVA inhibit recombinant T-type channels , 2022, Frontiers in Pharmacology.

[6]  K. Lovell,et al.  Synthesis and Inhibitory Activity of Machaeridiol-Based Novel Anti-MRSA and Anti-VRE Compounds and Their Profiling for Cancer-Related Signaling Pathways , 2022, Molecules.

[7]  Z. Liu,et al.  New cannabidiol (CBD) derivatives: Synthesis, anti-inflammatory activity, and molecular docking , 2022, Phytochemistry Letters.

[8]  D. Passarella,et al.  Stereoselective Synthetic Strategies to (−)‐Cannabidiol , 2022, ChemistrySelect.

[9]  M. McDonnell,et al.  Anti-Inflammatory Properties of KLS-13019: a Novel GPR55 Antagonist for Dorsal Root Ganglion and Hippocampal Cultures , 2022, Journal of Molecular Neuroscience.

[10]  R. Pertwee,et al.  Motor-like Tics are Mediated by CB2 Cannabinoid Receptor-dependent and Independent Mechanisms Associated with Age and Sex , 2022, Molecular Neurobiology.

[11]  E. Denovan‐Wright,et al.  Synthetic cannabinoids reduce the inflammatory activity of microglia and subsequently improve neuronal survival in vitro , 2022, Brain, Behavior, and Immunity.

[12]  Shiyu Jin,et al.  Pharmacological Activation of GPR55 Improved Cognitive Impairment Induced by Lipopolysaccharide in Mice , 2022, Journal of Molecular Neuroscience.

[13]  L. Lo Presti,et al.  Total Synthesis of (‐)‐Cannabidiol‐C4 , 2022, European Journal of Organic Chemistry.

[14]  Rui Yu,et al.  The neuroprotective effects of GPR55 against hippocampal neuroinflammation and impaired adult neurogenesis in CSDS mice , 2022, Neurobiology of Disease.

[15]  R. Vishwakarma,et al.  Stereoselective Synthesis of Nonpsychotic Natural Cannabidiol and Its Unnatural/Terpenyl/Tail-Modified Analogues. , 2022, The Journal of organic chemistry.

[16]  D. Meltzer,et al.  Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. , 2022, Science advances.

[17]  P. Basu,et al.  Autism and associated disorders: cannabis as a potential therapy. , 2022, Frontiers in bioscience.

[18]  Shiyu Jin,et al.  Activation of GPR55 attenuates cognitive impairment, oxidative stress, neuroinflammation, and synaptic dysfunction in a streptozotocin-induced Alzheimer's mouse model , 2022, Pharmacology Biochemistry and Behavior.

[19]  F. Guimarães,et al.  The Cannabidiol Analog PECS-101 Prevents Chemotherapy-Induced Neuropathic Pain via PPARγ Receptors , 2021, Neurotherapeutics.

[20]  S. Romero-Zerbo,et al.  Abnormal cannabidiol ameliorates inflammation preserving pancreatic beta cells in mouse models of experimental type 1 diabetes and beta cell damage. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[21]  R. Enciso,et al.  Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis , 2021, Journal of dental anesthesia and pain medicine.

[22]  G. Appendino,et al.  EHP-101 alleviates angiotensin II-induced fibrosis and inflammation in mice. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[23]  Shiyu Jin,et al.  Activation of GPR55 attenuates cognitive impairment and neurotoxicity in a mouse model of Alzheimer's disease induced by Aβ1–42 through inhibiting RhoA/ROCK2 pathway , 2021, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[24]  Dong Fu,et al.  Cytochrome P450–Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol , 2021, Drug Metabolism and Disposition.

[25]  R. Mechoulam,et al.  Assessing the treatment of cannabidiolic acid methyl ester: a stable synthetic analogue of cannabidiolic acid on c-Fos and NeuN expression in the hypothalamus of rats , 2021, Journal of Cannabis Research.

[26]  G. Appendino,et al.  Cannabinoquinones: Synthesis and Biological Profile , 2021, Biomolecules.

[27]  A. Rolland,et al.  Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson’s Disease , 2021, Molecules.

[28]  B. Fiebich,et al.  (+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB1R antagonist/CB2R agonist that prevents diabetic nephropathy in mice. , 2021, Pharmacological research.

[29]  M. Elsohly,et al.  Cannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis , 2021, Molecules.

[30]  D. Brenneman,et al.  Behavioural and pharmacological effects of cannabidiol (CBD) and the cannabidiol analogue KLS‐13019 in mouse models of pain and reinforcement , 2021, British journal of pharmacology.

[31]  R. Mechoulam,et al.  Cannabinoid Quinones—A Review and Novel Observations , 2021, Molecules.

[32]  Kwang-Hyeon Liu,et al.  O-1602 Promotes Hepatic Steatosis through GPR55 and PI3 Kinase/Akt/SREBP-1c Signaling in Mice , 2021, International journal of molecular sciences.

[33]  A. Ramazani,et al.  A review on the syntheses of Dronabinol and Epidiolex as classical cannabinoids with various biological activities including those against SARS-COV2 , 2021, Journal of the Iranian Chemical Society.

[34]  P. Allegrini,et al.  A Novel and Practical Continuous Flow Chemical Synthesis of Cannabidiol (CBD) and its CBDV and CBDB Analogues , 2021 .

[35]  L. Pazdera,et al.  A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures , 2021, Cannabis and cannabinoid research.

[36]  F. O. Holguin,et al.  Using (+)-Carvone to access novel derivatives of (+)-ent-Cannabidiol: the first asymmetric syntheses of (+)-ent-CBDP and (+)-ent-CBDV. , 2021, Tetrahedron letters.

[37]  I. McGregor,et al.  Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review , 2021, Neuroscience & Biobehavioral Reviews.

[38]  R. Marks,et al.  The effect of cannabis toxicity on a model microbiome bacterium epitomized by a panel of bioluminescent E. coli. , 2021, Chemosphere.

[39]  M. Beenhakker,et al.  Cannabidiolic acid exhibits entourage-like improvements of anticonvulsant activity in an acute rat model of seizures , 2020, Epilepsy Research.

[40]  G. Gigli,et al.  Identification of a new cannabidiol n-hexyl homolog in a medicinal cannabis variety with an antinociceptive activity in mice: cannabidihexol , 2020, Scientific Reports.

[41]  L. Devi,et al.  Diversity of molecular targets and signaling pathways for CBD , 2020, Pharmacology research & perspectives.

[42]  J. Manzanares,et al.  Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders , 2020, Biomolecules.

[43]  D. Vigli,et al.  Chronic Treatment with Cannabidiolic Acid (CBDA) Reduces Thermal Pain Sensitivity in Male Mice and Rescues the Hyperalgesia in a Mouse Model of Rett Syndrome , 2020, Neuroscience.

[44]  A. McAinch,et al.  The Role of Atypical Cannabinoid Ligands O-1602 and O-1918 on Skeletal Muscle Homeostasis with a Focus on Obesity , 2020, International journal of molecular sciences.

[45]  Eduardo Orrego-González,et al.  Cannabinoid Effects on Experimental Colorectal Cancer Models Reduce Aberrant Crypt Foci (ACF) and Tumor Volume: A Systematic Review , 2020, Evidence-based complementary and alternative medicine : eCAM.

[46]  L. Fusar-Poli,et al.  Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies , 2020, Brain sciences.

[47]  D. Ulrich,et al.  O-1602, an Agonist of Atypical Cannabinoid Receptors GPR55, Reverses the Symptoms of Depression and Detrusor Overactivity in Rats Subjected to Corticosterone Treatment , 2020, Frontiers in Pharmacology.

[48]  C. Svensson.  CBD for the treatment of pain: What is the evidence? , 2020, Journal of the American Pharmacists Association : JAPhA.

[49]  P. Radziszewski,et al.  The effect of O-1602, a GPR55 agonist, on the cyclophosphamide-induced rat hemorrhagic cystitis. , 2020, European journal of pharmacology.

[50]  O. Valverde,et al.  BEHAVIOURAL AND MOLECULAR EFFECTS OF CANNABIDIOLIC ACID IN MICE , 2020, bioRxiv.

[51]  M. Pirrung.  Synthetic Access to Cannabidiol and Analogs As Active Pharmaceutical Ingredients. , 2020, Journal of medicinal chemistry.

[52]  M. Catauro,et al.  (‒)-Cannabidiolic Acid, a Still Overlooked Bioactive Compound: An Introductory Review and Preliminary Research , 2020, Molecules.

[53]  N. Teixeira,et al.  Cannabis sativa: much more beyond Δ9-tetrahydrocannabinol. , 2020, Pharmacological research.

[54]  S. Romero-Zerbo,et al.  The Atypical Cannabinoid Abn-CBD Reduces Inflammation and Protects Liver, Pancreas, and Adipose Tissue in a Mouse Model of Prediabetes and Non-alcoholic Fatty Liver Disease , 2020, Frontiers in Endocrinology.

[55]  Chengyuan Liang,et al.  Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease. , 2020, European journal of medicinal chemistry.

[56]  S. Petrosino,et al.  Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets. , 2020, Biochemical pharmacology.

[57]  B. Vissel,et al.  Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia , 2020, Neurobiology of Disease.

[58]  R. Urman,et al.  The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence , 2020, Current Pain and Headache Reports.

[59]  L. Mestre,et al.  Effects of EHP-101 on inflammation and remyelination in murine models of Multiple sclerosis , 2020, Neurobiology of Disease.

[60]  F. Dehghani,et al.  Abnormal Cannabidiol Affects Production of Pro-Inflammatory Mediators and Astrocyte Wound Closure in Primary Astrocytic-Microglial Cocultures , 2020, Molecules.

[61]  H. Aisa,et al.  Synthesis of CBD and Its Derivatives Bearing Various C4'-side Chains with a Late-Stage Diversification Method. , 2019, The Journal of organic chemistry.

[62]  R. Mechoulam,et al.  Sleep and neurochemical modulation by cannabidiolic acid methyl ester in rats , 2019, Brain Research Bulletin.

[63]  HuiChao Wang,et al.  Effects of O‐1602 and CBD on TNBS‐induced colonic disturbances , 2019, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[64]  G. Gigli,et al.  A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol , 2019, Scientific Reports.

[65]  L. Degenhardt,et al.  Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. , 2019, The lancet. Psychiatry.

[66]  I. Choi,et al.  Synthetic Strategies for (-)-Cannabidiol and Its Structural Analogs. , 2019, Chemistry, an Asian journal.

[67]  J. Achenbach,et al.  Antitumor Activity of Abnormal Cannabidiol and Its Analog O-1602 in Taxol-Resistant Preclinical Models of Breast Cancer , 2019, Front. Pharmacol..

[68]  R. Capasso,et al.  The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients. , 2019, Pharmacological research.

[69]  G. Gigli,et al.  Chemical and spectroscopic characterization data of ‘cannabidibutol’, a novel cannabidiol butyl analog , 2019, Data in brief.

[70]  S. Bonaccorso,et al.  Cannabidiol (CBD) use in psychiatric disorders: A systematic. , 2019, Neurotoxicology.

[71]  Y. Kwan,et al.  G-protein coupled receptor 55 agonists increase insulin secretion through inositol trisphosphate-mediated calcium release in pancreatic β-cells. , 2019, European journal of pharmacology.

[72]  M. Dallas,et al.  Synthetic, non-intoxicating 8,9-dihydrocannabidiol for the mitigation of seizures , 2019, Scientific Reports.

[73]  D. Brenneman,et al.  Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity , 2019, Journal of Molecular Neuroscience.

[74]  J. Fernández-Ruiz,et al.  Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP‐43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis , 2019, British journal of pharmacology.

[75]  P. Forcelli,et al.  Preclinical safety and efficacy of cannabidivarin for early life seizures , 2019, Neuropharmacology.

[76]  Y. Kwan,et al.  Novel protective effect of O-1602 and abnormal cannabidiol, GPR55 agonists, on ER stress-induced apoptosis in pancreatic β-cells. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[77]  G. Appendino,et al.  Cannabinoid derivatives acting as dual PPAR&ggr;/CB2 agonists as therapeutic agents for systemic sclerosis , 2019, Biochemical pharmacology.

[78]  F. Guimarães,et al.  DMH‐CBD, a cannabidiol analog with reduced cytotoxicity, inhibits TNF production by targeting NF‐kB activity dependent on A2A receptor , 2019, Toxicology and applied pharmacology.

[79]  A. McAinch,et al.  Atypical cannabinoid ligands O-1602 and O-1918 administered chronically in diet-induced obesity , 2019, Endocrine connections.

[80]  M. Baciut,et al.  Cannabinoids and bone regeneration , 2019, Drug metabolism reviews.

[81]  Z. Song,et al.  Novel inverse agonists for the orphan G protein-coupled receptor 6 , 2018, Heliyon.

[82]  G. Appendino,et al.  EHP‐101, an oral formulation of the cannabidiol aminoquinone VCE‐004.8, alleviates bleomycin‐induced skin and lung fibrosis , 2018, Biochemical pharmacology.

[83]  M. J. Vazquez,et al.  VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity , 2018, Scientific Reports.

[84]  F. Guimarães,et al.  Neuronal preservation and reactive gliosis attenuation following neonatal sciatic nerve axotomy by a fluorinated cannabidiol derivative , 2018, Neuropharmacology.

[85]  C. Raggi,et al.  Chronic treatment with the phytocannabinoid Cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome , 2018, Neuropharmacology.

[86]  G. Appendino,et al.  VCE‐004.3, a cannabidiol aminoquinone derivative, prevents bleomycin‐induced skin fibrosis and inflammation through PPARγ‐ and CB2 receptor‐dependent pathways , 2018, British journal of pharmacology.

[87]  D. Brenneman,et al.  Pharmacological Comparisons Between Cannabidiol and KLS-13019 , 2018, Journal of Molecular Neuroscience.

[88]  Barry N. Dungan,et al.  Lewis-Acid-Mediated Union of Epoxy-Carvone Diastereomers with Anisole Derivatives: Mechanistic Insight and Application to the Synthesis of Non-natural CBD Analogues. , 2018, Organic letters.

[89]  S. Giofrè,et al.  Inhibition of aldose reductase activity by Cannabis sativa chemotypes extracts with high content of cannabidiol or cannabigerol. , 2018, Fitoterapia.

[90]  F. Mach,et al.  The quest for endothelial atypical cannabinoid receptor: BKCa channels act as cellular sensors for cannabinoids in in vitro and in situ endothelial cells. , 2018, Vascular pharmacology.

[91]  G. Heeba,et al.  Abnormal cannabidiol confers cardioprotection in diabetic rats independent of glycemic control , 2018, European journal of pharmacology.

[92]  D. Thapa,et al.  The Cannabinoids Δ8THC, CBD, and HU-308 Act via Distinct Receptors to Reduce Corneal Pain and Inflammation , 2018, Cannabis and cannabinoid research.

[93]  J. Jacobson,et al.  Enantioselective Total Synthesis of Cannabinoids-A Route for Analogue Development. , 2018, Organic letters.

[94]  C. Limebeer,et al.  Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5‐HT1A receptor‐mediated suppression of nausea and anxiety in rats , 2018, British journal of pharmacology.

[95]  M. Balíková,et al.  Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC , 2017, European Neuropsychopharmacology.

[96]  F. Guimarães,et al.  Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative , 2017, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[97]  C. Müller,et al.  GPR55: A therapeutic target for Parkinson's disease? , 2017, Neuropharmacology.

[98]  T. Bíró,et al.  460 Assessment of the anti-inflammatory effects of fluorinated semi-synthetic phytocannabinoids in human in vitro inflammatory keratinocyte model systems , 2017 .

[99]  E. Chow,et al.  A selective review of medical cannabis in cancer pain management. , 2017, Annals of palliative medicine.

[100]  P. Morales,et al.  An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol , 2017, Front. Pharmacol..

[101]  D. Friedman,et al.  Pharmacology of cannabinoids in the treatment of epilepsy , 2017, Epilepsy & Behavior.

[102]  C. Limebeer,et al.  Cannabinoid 2 (CB2) receptor agonism reduces lithium chloride-induced vomiting in Suncus murinus and nausea-induced conditioned gaping in rats. , 2016, European journal of pharmacology.

[103]  Regina M. Krohn,et al.  Abnormal cannabidiol attenuates experimental colitis in mice, promotes wound healing and inhibits neutrophil recruitment , 2016, Journal of Inflammation.

[104]  F. Guimarães,et al.  Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects , 2016, PloS one.

[105]  J. Elverdín,et al.  Anti-Inflammatory and Osteoprotective Effects of Cannabinoid-2 Receptor Agonist HU-308 in a Rat Model of Lipopolysaccharide-Induced Periodontitis. , 2016, Journal of periodontology.

[106]  Z. Vogel,et al.  Anti-inflammatory effects of the cannabidiol derivative dimethylheptyl-cannabidiol – studies in BV-2 microglia and encephalitogenic T cells , 2016, Journal of basic and clinical physiology and pharmacology.

[107]  G. Appendino,et al.  The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways , 2016, Scientific Reports.

[108]  Tao Qian,et al.  Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability. , 2016, ACS medicinal chemistry letters.

[109]  Z. Vogel,et al.  HU‐446 and HU‐465, Derivatives of the Non‐psychoactive Cannabinoid Cannabidiol, Decrease the Activation of Encephalitogenic T Cells , 2016, Chemical biology & drug design.

[110]  H. Aramaki,et al.  Cannabidiol-2',6'-dimethyl ether stimulates body weight gain in apolipoprotein E-deficient BALB/c. KOR/Stm Slc-Apoe(shl) mice. , 2015, The Journal of toxicological sciences.

[111]  M. Feldmann,et al.  HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[112]  M. Dallas,et al.  Molecular Targets of Cannabidiol in Neurological Disorders , 2015, Neurotherapeutics.

[113]  M. Cascio,et al.  CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency , 2015, Proceedings of the National Academy of Sciences.

[114]  D. Su,et al.  Activation of cannabinoid receptor 2 attenuates synovitis and joint distruction in collagen-induced arthritis. , 2015, Immunobiology.

[115]  S. Mercer,et al.  HU-331 is a catalytic inhibitor of topoisomerase IIα. , 2014, Chemical research in toxicology.

[116]  H. Aramaki,et al.  Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells. , 2014, The Journal of toxicological sciences.

[117]  R. Bergman,et al.  Obesity, insulin resistance and comorbidities? Mechanisms of association. , 2014, Arquivos brasileiros de endocrinologia e metabologia.

[118]  E. Brǎiloiu,et al.  Activation of GPR18 by cannabinoid compounds: a tale of biased agonism , 2014, British journal of pharmacology.

[119]  Dao-Yi Yu,et al.  Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature. , 2014, European journal of pharmacology.

[120]  S. Yamaori,et al.  Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. , 2014, Chemico-biological interactions.

[121]  P. Hazelton,et al.  Prospects for cannabinoid therapies in viral encephalitis , 2013, Brain Research.

[122]  E. Rock,et al.  Suppression of lithium chloride-induced conditioned gaping (a model of nausea-induced behaviour) in rats (using the taste reactivity test) with metoclopramide is enhanced by cannabidiolic acid , 2013, Pharmacology Biochemistry and Behavior.

[123]  Makoto Tsunozaki,et al.  TRPA1: A gatekeeper for inflammation. , 2013, Annual review of physiology.

[124]  Shane M. Wilkinson,et al.  Improved accessibility to the desoxy analogues of Δ9-tetrahydrocannabinol and cannabidiol , 2013 .

[125]  F. Guimarães,et al.  Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors. , 2012, Journal of psychiatric research.

[126]  Akhilesh Kumar,et al.  Involvement of a non-CB1/CB2 cannabinoid receptor in the aqueous humor outflow-enhancing effects of abnormal-cannabidiol. , 2012, Experimental eye research.

[127]  M. Neurath,et al.  TRPA1 and substance P mediate colitis in mice. , 2011, Gastroenterology.

[128]  K. Mackie,et al.  The atypical cannabinoid O‐1602 protects against experimental colitis and inhibits neutrophil recruitment , 2011, Inflammatory bowel diseases.

[129]  T. Bisogno,et al.  Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes , 2011, British journal of pharmacology.

[130]  Y. Fukunishi,et al.  Cannabidiol-2',6'-dimethyl ether as an effective protector of 15-lipoxygenase-mediated low-density lipoprotein oxidation in vitro. , 2011, Biological & pharmaceutical bulletin.

[131]  J. McDougall,et al.  The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55 , 2011, Neuroscience Letters.

[132]  H. Qian,et al.  Activation of cannabinoid receptor CB2 regulates osteogenic and osteoclastogenic gene expression in human periodontal ligament cells. , 2010, Journal of periodontal research.

[133]  R. Capasso,et al.  Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. , 2009, Trends in pharmacological sciences.

[134]  K. Mackie,et al.  The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo , 2009, Proceedings of the National Academy of Sciences.

[135]  I. Yamamoto,et al.  Cannabidiol-2′,6′-Dimethyl Ether, a Cannabidiol Derivative, Is a Highly Potent and Selective 15-Lipoxygenase Inhibitor , 2009, Drug Metabolism and Disposition.

[136]  L. Steardo,et al.  Cannabidiol: A Promising Drug for Neurodegenerative Disorders? , 2009, CNS neuroscience & therapeutics.

[137]  A. Deiters,et al.  A cyclotrimerization route to cannabinoids. , 2008, Organic letters.

[138]  R. Pertwee,et al.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin , 2008 .

[139]  Pál Pacher,et al.  Pivotal Advance: Cannabinoid‐2 receptor agonist HU‐308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis , 2007 .

[140]  S. Dowell,et al.  The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects , 2007, British journal of pharmacology.

[141]  F. Diederich,et al.  Fluorine in Pharmaceuticals: Looking Beyond Intuition , 2007, Science.

[142]  S. Nikas,et al.  C1'-cycloalkyl side chain pharmacophore in tetrahydrocannabinols. , 2007, Journal of medicinal chemistry.

[143]  R. Mechoulam,et al.  A Cannabinoid Anticancer Quinone, HU-331, Is More Potent and Less Cardiotoxic Than Doxorubicin: A Comparative in Vivo Study , 2007, Journal of Pharmacology and Experimental Therapeutics.

[144]  S. Morimoto,et al.  Cannabidiolic‐acid synthase, the chemotype‐determining enzyme in the fiber‐type Cannabis sativa , 2007, FEBS letters.

[145]  Jiyue Zheng,et al.  A general route to 5,6-seco-hexahydrodibenzopyrans and analogues: first total synthesis of (+)-Machaeridiol B and (+)-Machaeriol B , 2007 .

[146]  M. Guzmán,et al.  A Cannabinoid Quinone Inhibits Angiogenesis by Targeting Vascular Endothelial Cells , 2006, Molecular Pharmacology.

[147]  A. Takeuchi,et al.  Synthesis of cannabidiols via alkenylation of cyclohexenyl monoacetate. , 2006, Organic letters.

[148]  S. Ben-Shabat,et al.  New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. , 2006, Journal of medicinal chemistry.

[149]  M. Elsohly,et al.  Chemical constituents of marijuana: the complex mixture of natural cannabinoids. , 2005, Life sciences.

[150]  D. Ponde,et al.  Peripheral, but not central effects of cannabidiol derivatives: Mediation by CB1 and unidentified receptors , 2005, Neuropharmacology.

[151]  Raphael Mechoulam,et al.  Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors. , 2005, Organic & biomolecular chemistry.

[152]  D. Gibson,et al.  Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. , 2004, Journal of medicinal chemistry.

[153]  G. Kunos,et al.  Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. , 2004, European journal of pharmacology.

[154]  M. Feldmann,et al.  A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. , 2004, Arthritis and rheumatism.

[155]  B. Tekwani,et al.  Antimicrobial and antiparasitic (+)-trans-hexahydrodibenzopyrans and analogues from Machaerium multiflorum. , 2003, Journal of natural products.

[156]  R. Mechoulam,et al.  Synthesis of a primary metabolite of cannabidiol. , 2000, Organic letters.

[157]  R. Mechoulam.  Looking back at Cannabis research. , 2000, Current pharmaceutical design.

[158]  Lei Wang,et al.  Cardiovascular effects of endocannabinoids--the plot thickens. , 2000, Prostaglandins & other lipid mediators.

[159]  R. Mechoulam,et al.  HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[160]  I. Yamamoto,et al.  Synthesis and pharmacological evaluation in mice of halogenated cannabidiol derivatives. , 1999, Chemical & pharmaceutical bulletin.

[161]  I. Yamamoto,et al.  Synthesis and pharmacological activities in mice of halogenated delta 9-tetrahydrocannabinol derivatives. , 1998, Chemical & pharmaceutical bulletin.

[162]  R. Pertwee,et al.  The design, synthesis and testing of desoxy-CBD: further evidence for a region of steric interference at the cannabinoid receptor. , 1995, Life sciences.

[163]  I. Yamamoto,et al.  Synthesis and pharmacological effects in mice of halogenated cannabinol derivatives. , 1995, Chemical & pharmaceutical bulletin.

[164]  M. Correia,et al.  Characterization of cannabidiol-mediated cytochrome P450 inactivation. , 1993, Biochemical pharmacology.

[165]  V. Vaillancourt,et al.  A One‐Step Method for the α‐Arylation of Camphor. Synthesis of (‐ )‐Cannabidiol and (+)‐Cannabidiol Dimethyl Ether. , 1992 .

[166]  K. Albizati,et al.  A one-step method for the .alpha.-arylation of camphor. Synthesis of (-)-cannabidiol and (-)-cannabidiol dimethyl ether. , 1992 .

[167]  I. Yamamoto,et al.  Cannabielsoin as a new metabolite of cannabidiol in mammals , 1991, Pharmacology Biochemistry and Behavior.

[168]  A. Hiltunen,et al.  Enantiomeric cannabinoids: stereospecificity of psychotropic activity , 1988, Experientia.

[169]  L. Crombie,et al.  Terpenylations Using (R)‐(‐)‐α‐Phellandrene. Synthesis of the (3S,4R)‐8,9‐Dihydro‐o‐ and ‐p‐cannabidiols, Their iso‐THC′s, and the Natural Dihydrochalcone (3S,4R)‐(+)‐Linderatin. , 1988 .

[170]  K. Tamao,et al.  (Diisopropoxymethylsilyl)methyl Grignard reagent: a new, practically useful nucleophilic hydroxymethylating agent , 1983 .

[171]  C. Bercht,et al.  CANNABINODIOL- CONCLUSIVE IDENTIFICATION AND SYNTHESIS OF A NEW CANNABINOID FROM CANNABIS SATIVA , 1977 .

[172]  R. Razdan,et al.  HASHISH PART 10, A SIMPLE ONE-STEP SYNTHESIS OF (-)-DELTA(1)-TETRAHYDROCANNABINOL (THC) FROM P-MENTHA-2,8-DIEN-1-OL AND OLIVETOL , 1974 .

[173]  E. R. Garrett,et al.  Physicochemical Properties, Solubility, and Protein Binding of Δ9 -Tetrahydrocannabinol , 1974 .

[174]  S. Servi,et al.  Alkylation of resorcinols with monoterpenoid allylic alcohols in aqueous acid. Synthesis of new cannabinoid derivatives , 1973 .

[175]  R. Mechoulam,et al.  The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. , 1971, Journal of the American Chemical Society.

[176]  R. Mechoulam,et al.  A TOTAL SYNTHESIS OF DL-DELTA-1-TETRAHYDROCANNABINOL, THE ACTIVE CONSTITUENT OF HASHISH. , 1965, Journal of the American Chemical Society.

[177]  R. Adams,et al.  Structure of Cannabinol. III. Synthesis of Cannabinol, 1-Hydroxy-3-n-amyl-6,6,9-trimethyl-6-dibenzopyran1 , 1940 .

[178]  J. Marcu,et al.  Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads. , 2017, Advances in pharmacology.

[179]  S. Yamaori,et al.  Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. , 2013, Drug metabolism and pharmacokinetics.

[180]  Shuso Takeda.  [Medicinal chemistry and pharmacology focused on cannabidiol, a major component of the fiber-type cannabis]. , 2013, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[181]  N. Kitteringham,et al.  Metabolism of fluorine-containing drugs. , 2001, Annual review of pharmacology and toxicology.

[182]  Raphael Mechoulam,et al.  Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative , 1990 .

[183]  T. Umemoto,et al.  N-fluoropyridinium triflate and its derivatives: useful fluorinating agents , 1986 .

[184]  J. Leite,et al.  Anticonvulsant effects of the (-) and (+)isomers of cannabidiol and their dimethylheptyl homologs. , 1982, Pharmacology.

[185]  R. Mechoulam,et al.  Carboxylation of resorcinols with methylmagnesium carbonate. Synthesis of cannabinoid acids , 1969 .

[186]  T. Petrzilka,et al.  Synthese von Haschisch-Inhaltsstoffen. 4. Mitteilung , 1969 .

[187]  R. Mechoulam,et al.  The ISO‐Tetrahydrocannabinols , 1968 .

[188]  A. Eschenmoser,et al.  Synthese und Chiralität des (-)-Cannabidiols Vorläufige Mitteilung , 1967 .

[189]  R. Mechoulam,et al.  Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. , 1965, Tetrahedron.